A New Dosing Regimen for Nivolumab Plus Ipilimumab in Advanced Melanoma

A New Dosing Regimen for Nivolumab Plus Ipilimumab in Advanced Melanoma

Publication date: Mar 08, 2019

Concepts Keywords
Clinical trial Gp100:209-217
ClinicalTrials.gov Checkpoint inhibitor
Nivolumab
Ipilimumab
Monoclonal antibodies
Melanoma
Breakthrough therapy
Antineoplastic drugs
Cancer treatments
Clinical medicine
Bristol-Myers Squibb

Semantics

Type Source Name
pathway BSID Melanoma
disease MESH Melanoma
disease DOID Melanoma
drug DRUGBANK Ipilimumab
drug DRUGBANK Nivolumab

Similar

Leave a Comment

Your email address will not be published. Required fields are marked *